Latest / Stock Movers / Novartis Slumps, Sandoz Gains, Computacenter Up
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio, news.
- 0:08Speaker 2: The Stock Movers Report, your roundup of companies making moves
- 0:12Speaker 2: in the stock market, harnessing the power of Bloomberg data.
- 0:16Speaker 3: Well, let's take a look at some stocks on the
- 0:18Speaker 3: move today in Europe. I'm Stephen Carroll, and I'm joined
- 0:20Speaker 3: by our reporter, Chloe Mele. For more, Chloe, good morning.
- 0:23Speaker 3: Novartis shares slumping after a drug trial failure.
- 0:27Speaker 1: What's going on?
- 0:28Speaker 4: Yeah, it's been quite a tough week so far for
- 0:31Speaker 4: Novartis and we're only two days into the week. So yesterday,
- 0:34Speaker 4: it fell quite significantly already because of two failed drug
- 0:38Speaker 4: trials within the space of a few days.
- 0:40Speaker 1: And then today, there's another trial setback.
- 0:43Speaker 4: So now it's three setbacks within the space of just
- 0:47Speaker 4: about a week. So this particular setback, it was for
- 0:50Speaker 4: a treatment for a muscle wasting disease and the medicine
- 0:54Speaker 4: failed in a late stage of study. So This particular
- 0:57Speaker 4: setback for Novartis is potentially even worse than the other
- 1:01Speaker 4: ones because this particular medicine was really the centerpiece of
- 1:06Speaker 4: the company's $ 12 billion takeover of Avidity Biosciences. And it's
- 1:11Speaker 4: a drug that had been thought really as a potential blockbuster.
- 1:14Speaker 4: The CEO had told Bloomberg TV back in July yesterday,
- 1:18Speaker 4: that this was a drug that had, you know, sales
- 1:20Speaker 4: potential of $ 5 billion or more. So, now that ambition
- 1:24Speaker 4: will have to certainly be revised down. And so, analysts
- 1:28Speaker 4: are saying this is, you know, major pipeline setback and
- 1:31Speaker 4: that has not really helped their confidence in the other
- 1:35Speaker 4: therapies that Novartis has gained through this avidity takeover.
- 1:40Speaker 1: And now, there's going to be really renewed.
- 1:42Speaker 4: Worries about sources of growth for Novartis going forward and
- 1:46Speaker 4: especially beyond 2030 because a bunch of its best-selling drugs
- 1:50Speaker 4: are facing a patent cliff and the biggest patent cliff
- 1:54Speaker 4: in its history. So, that's going to be a bit
- 1:57Speaker 4: of trouble for Novartis. And we are seeing those setbacks
- 2:01Speaker 4: really weigh on the shares this morning.
- 2:03Speaker 2: Okay.
- 2:03Speaker 3: Well, that's Novartis. Meanwhile, Sandoz, which is formerly part of Novartis,
- 2:07Speaker 3: is enjoying opposite fortunes. What's going on there?
- 2:10Speaker 4: Yeah, Sandoz is doing much better. It raised its medium-term guidance.
- 2:13Speaker 4: It also set a new, very ambitious pipeline target. So,
- 2:18Speaker 4: Sandoz makes biosimilars, which is a biological medical product that
- 2:22Speaker 4: is highly similar to an already approved original reference product.
- 2:28Speaker 4: And so, it wants to increase the number of biosimilars
- 2:31Speaker 4: that it makes to more than 100 by 2040. from
- 2:36Speaker 4: just 13 currently. So, it wants that huge increase in
- 2:39Speaker 4: that portfolio. And it is investing around $ 300 million in
- 2:44Speaker 4: a biosimilars facility in Slovenia. There's going to be as
- 2:48Speaker 4: well a very big opportunity coming for that company with
- 2:52Speaker 4: GRP-1s as well, because the patents for semaglutide, which is
- 2:55Speaker 4: the key ingredient for Zempic, that has started to expire
- 3:00Speaker 4: in some countries. And so, that's paving the way for
- 3:03Speaker 4: generic drug companies like Sandoz to sell cheaper versions of
- 3:07Speaker 4: this key ingredient.
- 3:08Speaker 1: And so, that will make probably a big difference in
- 3:11Speaker 1: the outlook.
- 3:12Speaker 4: And that's going to be really a big opportunity for
- 3:15Speaker 4: that company and some of its peers as well.
- 3:18Speaker 3: Okay. And finally, computer center in the UK seeing a boost.
- 3:21Speaker 3: What's driving the rally? Is it computers by any chance?
- 3:24Speaker 1: Yes, it is indeed.
- 3:25Speaker 4: Well, it is an IT company which raised its guidance
- 3:28Speaker 4: once again. So, it already had raised its guidance back
- 3:31Speaker 4: in July.
- 3:32Speaker 1: It's done it again today. And so, we are seeing
- 3:34Speaker 1: the shares hit a record as a result of that.
- 3:36Speaker 4: So, the main growth driver for that company has been
- 3:41Speaker 4: demand from hyperscalers in the U.S. So, Computer Center is
- 3:45Speaker 4: essentially one of those slightly lesser-known AI winners. It's selling
- 3:49Speaker 4: data center infrastructure like servers, other types of hardware. And
- 3:54Speaker 4: then also software integration services to those hyperscalers. And it
- 3:58Speaker 4: has a really well-established presence in the West Coast of
- 4:01Speaker 4: the U.S.
- 4:02Speaker 1: As well, where a lot of those big tech companies
- 4:05Speaker 1: are based.
- 4:06Speaker 4: And so, analysts are saying that the order book is
- 4:08Speaker 4: very strong, that momentum is very solid, and that the
- 4:11Speaker 4: performance is actually outperforming already very elevated investor expectations. And so,
- 4:18Speaker 4: we're seeing shares up almost 100% so far in 2026.
- 4:23Speaker 4: And given this race guidance and this enthusiasm from all
- 4:27Speaker 4: of those analysts and investors, it seems that they might
- 4:29Speaker 4: be even further to go for Computer Center.
- 4:33Speaker 2: The Stock Movers Report from Bloomberg Radio. Check back with
- 4:37Speaker 2: us throughout the day for the latest roundup of companies
- 4:40Speaker 2: making news on Wall Street. And for the latest market-moving headlines,
- 4:44Speaker 2: listen to Bloomberg Radio Live. Catch us on YouTube, Bloomberg.com,
- 4:49Speaker 2: and on Apple CarPlay and Android Auto with the Bloomberg
- 4:52Speaker 2: Business app.